Market Overview

UPDATE: Jefferies Raises PT on Humana Ahead of 2Q Earnings Report

Share:
Related HUM
Humana To Begin Covering Exact Science's Cologuard In 2017
Benzinga's Top Downgrades
Why Trump And The GOP Must Replace ObamaCare Now, In 2 Charts (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst David Windley reiterated a Buy rating on Humana (NYSE: HUM), and raised the price target from $95.00 to $98.00.

In the report, Jefferies noted, “We expect MCOs to report 2Q earnings upsides. MCO commentary suggests utilization remains favorable, corroborated by Tenet's weak inpatient volumes and ISRG's weak capital equipment sales. We also highlight hot topics and headlines ahead of a flurry of important events over the next several months. AET remains our top MCO pick. We are modestly raising PTs for Diversifieds (still trading at a discount) on more stable outlooks.”

Humana closed on Tuesday at $85.18.

Latest Ratings for HUM

DateFirmActionFromTo
Dec 2016Cantor FitzgeraldDowngradesBuyHold
Nov 2016Credit SuisseUpgradesNeutralOutperform
Nov 2016JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: David Windley JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!